API
< Back to situations

[PERSON]

Tirzepatide

Featured in 9 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [GB] [DE]

Expanding therapeutic uses and regulatory concerns for GLP-1

43 clusters · 180 sources · last updated

Latest: Semaglutide study shows BMI reduction in children with obesity

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

343 clusters · 1318 sources · last updated

Latest: FDA issues warning for GLP-1 drugs over vision loss risks

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt

[QUIET] [HEALTH] [US] [BR] [CN]

Retatrutide development and regulatory actions

6 clusters · 32 sources · last updated

Latest: Anvisa recalls weight loss drug ingredients due to storage issues

Retatrutide, an investigational synthetic peptide developed by Eli Lilly, is being studied for its metabolic potential in managing food regulation, sugar, and weight. As a triple receptor agonist, it mimics natural gut a

Also covered in